<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Immunocore</title>
	<atom:link href="http://www.immunocore.com/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.immunocore.com</link>
	<description>Overcoming immune tolerance to cancer</description>
	<lastBuildDate>Thu, 17 May 2012 14:02:36 +0000</lastBuildDate>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.3.2</generator>
		<item>
		<title>Revolutionary new cancer targeting technology described in Nature Medicine</title>
		<link>http://www.immunocore.com/company-news/revolutionary-new-cancer-targeting-technology-described-in-nature-medicine/</link>
		<comments>http://www.immunocore.com/company-news/revolutionary-new-cancer-targeting-technology-described-in-nature-medicine/#comments</comments>
		<pubDate>Tue, 08 May 2012 09:48:00 +0000</pubDate>
		<dc:creator>paul.newey</dc:creator>
				<category><![CDATA[Company News]]></category>

		<guid isPermaLink="false">http://www.immunocore.com/?p=1287</guid>
		<description><![CDATA[ A revolutionary cancer-targeting technology developed by researchers at Immunocore Limited has been described for the first time in the prestigious medical journal, Nature Medicine. The new reagents known as ImmTACs (Immune Mobilising mTCR against Cancer) mobilise T cells to kill cancer cells and overcome immune tolerance to cancer. For more information click on the link below:- [...]]]></description>
		<wfw:commentRss>http://www.immunocore.com/company-news/revolutionary-new-cancer-targeting-technology-described-in-nature-medicine/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Immunocore and SHIL scoop Genesis Awards 2011</title>
		<link>http://www.immunocore.com/company-news/immunocore-and-shil-scoop-genesis-awards-2011/</link>
		<comments>http://www.immunocore.com/company-news/immunocore-and-shil-scoop-genesis-awards-2011/#comments</comments>
		<pubDate>Tue, 14 Feb 2012 15:40:39 +0000</pubDate>
		<dc:creator>paul.newey</dc:creator>
				<category><![CDATA[Company News]]></category>

		<guid isPermaLink="false">http://www.immunocore.com/?p=1239</guid>
		<description><![CDATA[Oxford-based cancer therapeutics company Immunocore and Scottish Health Innovations (SHIL) were the winners at the coveted 2011 Genesis Awards, announced at a special Awards Dinner following the conclusion of Genesis 2011. Harriet Fear, CEO of One Nucleus said that competition was fierce and showed that despite the current economic downturn, there is a wealth of [...]]]></description>
		<wfw:commentRss>http://www.immunocore.com/company-news/immunocore-and-shil-scoop-genesis-awards-2011/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Eurostars award for imaging research</title>
		<link>http://www.immunocore.com/company-news/eurostars-award/</link>
		<comments>http://www.immunocore.com/company-news/eurostars-award/#comments</comments>
		<pubDate>Wed, 27 Apr 2011 12:56:31 +0000</pubDate>
		<dc:creator>paul.newey</dc:creator>
				<category><![CDATA[Company News]]></category>

		<guid isPermaLink="false">http://www.immunocore.com/?p=1056</guid>
		<description><![CDATA[Immunocore, together with the French pre-clinical imaging company Animascope, has been awarded a European Union Eurostars project award.  ]]></description>
		<wfw:commentRss>http://www.immunocore.com/company-news/eurostars-award/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>First-in-class exposure in man</title>
		<link>http://www.immunocore.com/company-news/first-in-class-exposure-in-man/</link>
		<comments>http://www.immunocore.com/company-news/first-in-class-exposure-in-man/#comments</comments>
		<pubDate>Thu, 09 Dec 2010 08:51:29 +0000</pubDate>
		<dc:creator>paul.newey</dc:creator>
				<category><![CDATA[Company News]]></category>

		<guid isPermaLink="false">http://www.immunocore.com/?p=966</guid>
		<description><![CDATA[The first three patients with melanoma have completed dosing in the IMCgp100 phase I trial in the UK. Enrolment is now open for the second cohort in which patients will be given a higher dose, as planned. This is the first milestone in a dose-finding study in patients with advanced malignant melanoma, designed to establish a tolerability of increasing doses of IMCgp100 When this arm of the study is complete, a second phase is planned to assess the effect of the selected dose on pharmacodynamic markers when given repeatedly to a larger group of patients.

]]></description>
		<wfw:commentRss>http://www.immunocore.com/company-news/first-in-class-exposure-in-man/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Grand Challenges Explorations Award for HIV</title>
		<link>http://www.immunocore.com/company-news/grand-challenges-explorations-grant-for-hiv-research/</link>
		<comments>http://www.immunocore.com/company-news/grand-challenges-explorations-grant-for-hiv-research/#comments</comments>
		<pubDate>Tue, 09 Nov 2010 17:30:47 +0000</pubDate>
		<dc:creator>paul.newey</dc:creator>
				<category><![CDATA[Company News]]></category>

		<guid isPermaLink="false">http://www.immunocore.com/?p=854</guid>
		<description><![CDATA[Immunocore announced today that it has received a US$100,000 Grand Challenges Explorations grant from the Bill &#038; Melinda Gates Foundation. The grant will support an innovative global health research project conducted by Dr. Bent Jakobsen, Chief Scientific Officer, titled “curing HIV through elimination of latently infected cells”.

]]></description>
		<wfw:commentRss>http://www.immunocore.com/company-news/grand-challenges-explorations-grant-for-hiv-research/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Clinical trials commence for melanoma in UK and USA</title>
		<link>http://www.immunocore.com/company-news/clinical-trials-commence-for-melanoma-in-uk-and-usa/</link>
		<comments>http://www.immunocore.com/company-news/clinical-trials-commence-for-melanoma-in-uk-and-usa/#comments</comments>
		<pubDate>Tue, 05 Oct 2010 14:39:47 +0000</pubDate>
		<dc:creator>paul.newey</dc:creator>
				<category><![CDATA[Company News]]></category>

		<guid isPermaLink="false">http://www.immunocore.com/?p=783</guid>
		<description><![CDATA[IMCgp100, a targeted therapeutic for the treatment of advanced metastatic melanoma, has entered clinical trials in the UK and USA. IMCgp100 is the first clinical candidate originating from Immunocore’s innovative ImmTAC technology platform and a new treatment could benefit many thousands of patients diagnosed with skin cancer each year.]]></description>
		<wfw:commentRss>http://www.immunocore.com/company-news/clinical-trials-commence-for-melanoma-in-uk-and-usa/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Lead Identification</title>
		<link>http://www.immunocore.com/immtac/lead-identification/</link>
		<comments>http://www.immunocore.com/immtac/lead-identification/#comments</comments>
		<pubDate>Wed, 11 Aug 2010 20:24:01 +0000</pubDate>
		<dc:creator>paul.newey</dc:creator>
				<category><![CDATA[ImmTac]]></category>

		<guid isPermaLink="false">http://immunocore.lbdesign.eu/?p=502</guid>
		<description><![CDATA[The first step is to identify and validate a T-cell clone specific for the desired epitope; this can either be generated in- house or in-licensed, as appropriate. The T-Cell Receptor (TCR) from the clone is then isolated and re-engineered into a soluble format through the introduction of a new inter-chain disulphide bond that is buried [...]]]></description>
		<wfw:commentRss>http://www.immunocore.com/immtac/lead-identification/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Lead Enhancement</title>
		<link>http://www.immunocore.com/immtac/lead-eenhancement/</link>
		<comments>http://www.immunocore.com/immtac/lead-eenhancement/#comments</comments>
		<pubDate>Tue, 10 Aug 2010 20:24:32 +0000</pubDate>
		<dc:creator>paul.newey</dc:creator>
				<category><![CDATA[ImmTac]]></category>

		<guid isPermaLink="false">http://immunocore.lbdesign.eu/?p=504</guid>
		<description><![CDATA[Like antibodies, TCRs contain 6 hypervariable complementary determining regions (CDRs) which form the binding epitope contact surface. Immunocore engineers these CDR regions to increase the affinity of the mTCR for its target while maintaining specificity, typically resulting in mTCRs with low pM affinities and long target residence times. Read more »]]></description>
		<wfw:commentRss>http://www.immunocore.com/immtac/lead-eenhancement/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>James Noble, CEO</title>
		<link>http://www.immunocore.com/management/james-noble-ceo/</link>
		<comments>http://www.immunocore.com/management/james-noble-ceo/#comments</comments>
		<pubDate>Tue, 10 Aug 2010 17:49:09 +0000</pubDate>
		<dc:creator>paul.newey</dc:creator>
				<category><![CDATA[Management]]></category>

		<guid isPermaLink="false">http://immunocore.lbdesign.eu/?p=441</guid>
		<description><![CDATA[James has been involved with Immunocore’s T cell receptor technology since 1999, when Avidex Limited (the predecessor company to Immunocore) was founded. He has over two decades of experience in biotechnology and has served on public and private boards of companies in the UK, the USA and Germany. He is currently Deputy Chairman at GW [...]]]></description>
		<wfw:commentRss>http://www.immunocore.com/management/james-noble-ceo/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>ASGCT 15th Annual Meeting and Course</title>
		<link>http://www.immunocore.com/next-event/asgct/</link>
		<comments>http://www.immunocore.com/next-event/asgct/#comments</comments>
		<pubDate>Tue, 10 Aug 2010 09:24:56 +0000</pubDate>
		<dc:creator>paul.newey</dc:creator>
				<category><![CDATA[Next Event]]></category>

		<guid isPermaLink="false">http://immunocore.lbdesign.eu/?p=402</guid>
		<description><![CDATA[]]></description>
		<wfw:commentRss>http://www.immunocore.com/next-event/asgct/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>

